Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries

BACKGROUND: Time to reimbursement (TTR) of new anticancer medicines differs between countries and contributes to unequal access. We aimed to investigate TTR of new anticancer medicines and explore factors influencing the reimbursement process in seven high-income European countries. MATERIALS AND ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Post, H.C., Schutte, T., van Oijen, M.G.H., van Laarhoven, H.W.M., Hollak, C.E.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163159/
https://www.ncbi.nlm.nih.gov/pubmed/37030113
http://dx.doi.org/10.1016/j.esmoop.2023.101208

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163159/
https://www.ncbi.nlm.nih.gov/pubmed/37030113
http://dx.doi.org/10.1016/j.esmoop.2023.101208

Ejemplares similares